1860-41-9

Upstream product

• 937-59-7 4-cyclohexylidenebutanal 
• 201230-82-2 carbon monoxide 
• 2114-42-3 allylcyclohexane 
• 4441-57-0 4-cyclohexylbutan-1-ol 
• 5364-83-0 1-cyclohexylprop-1-ene 
• 79-37-8 oxalyl dichloride 
• 110-83-8 cyclohexene 
• 2043-61-0 cyclohexanecarbaldehyde 

Downstream Products

• 301831-42-5 1-((E)-5-Cyclohexyl-pent-1-enyl)-4-nitro-benzene 
• 216087-38-6 1-cyclohexylheptan-3-ol 
• 2205-29-0 7-Cyclohexyl-heptandiol-(1,4) 
• 118325-48-7 2-bromo-4-cyclohexylbutylaldehyde 
• 130255-29-7 Methyl 4-hydroxy-5-cyclohexylpent-2-enoate 

Relevant academic research and scientific papers

CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF

The present application discloses a compound of formula (I) or a salt thereof: (I) and compositions comprising such compound or salt thereof. The use of such compound, salt thereof or composition comprising same for treating anemia or leukopenia, fibrosis, cancer, hypertension and/or a metabolic condition in a subject is also disclosed.

Phosphabarrelenes as ligands in rhodium-catalyzed hydroformylation of internal alkenes essentially free of alkene isomerization

Despite significant research efforts in the past, one of the remaining problems to be solved in industrially important hydroformylation is the chemoselective low-pressure hydroformylation of internal alkenes. We report here on a new class of phosphabarrelene/rhodium catalysts 2 that display very high activity towards hydroformylation of internal alkenes with an unusually low tendency towards alkene isomerization. Preparation of new phosphabarrelene ligands, studies of their coordination properties, as well as results obtained in the rhodium-catalyzed hydroformylation of cyclic and acyclic internal alkenes are reported.

DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

Thionin-sensitized intrazeolite photooxygenation of trisubstituted alkenes: Substituent effects on the regioselectivity as probed through isotopic labeling

The regioselectivity for the intrazeolite photooxygenation of several trisubstituted alkenes with geminal dimethyl groups was examined. The length of the alkyl chain at the lone position was varied, and as end groups, the phenyl or the cyclohexyl functionalities were chosen. The general trend for all alkenes is a significant increase of the reactivity at the twin position compared to the photooxygenation in solution. For the cyclohexyl-substituted alkenes, it was found that the regioselectivity is nearly independent of the alkyl chain length. However, for the phenyl-substituted alkenes, the ene reactivity of the allylic methylene hydrogen atoms at the lone position and the twix/twin regioselectivity depend significantly on the distance of the phenyl group from the double bond. These trends are discussed in terms of cation-π interactions and conformational effects. Intramolecular and intermolecular isotope effects in the intrazeolite photooxygenation of deuterium-labeled alkenes suggest that a perepoxide-type intermediate is formed in the rate-determining step. Type I photooxygenation that involves reaction of the radical cations of the alkenes with superoxide ion are unlikely.

Is a nitrogen atom an important pharmacophoric element in sigma ligand binding?

A lingering question in σ receptor ligand development is whether a nitrogen atom serves as an important pharmacophoric element in binding affinity. To address this question, we have synthesized several phenylalkylpiperidines and phenylalkylpiperazines and

1,4-DIHYDROPYRIDINE DERIVATIVES

A 1,4-dihydropyridine derivative having the formula (I): wherein, R1represents a substituted or unsubstituted phenyl or heterocyclic group, R2represents a C1to C5lower alkyl group, R3represents a substituted or unsubstituted C2to C8alkyl, alkenyl, alkynyl or substituted or unsubstituted cycloalkyl group, R4represents -A-R5, wherein A represents a C2to C8alkylene group or a substituted or unsubstituted C2to C8alkenylene group, and R5represents a substituted or unsubstituted pyridyl, pyridylcarbonyl or piperadinyl group and a drug for overcoming resistance to an anti-cancer drug or a drug increasing the effect of an anti-cancer drug containing as an effective ingredient the derivative or its pharmacologically acceptable salt or hydrate.

Rhodium-catalysed hydroformylation of branched 1-alkenes; bulky phosphite vs. triphenylphosphine as modifying ligand

The influence of alkyl substituents in 1-alkene substrates in the rhodium-catalysed hydroformylation in the presence of tris(2-tertbutyl-4-methylphenyl) phosphite has been studied and compared with that observed for the reaction involving the conventional PPh3-modified catalyst. Hindered alkenes underwent hydroformylation at good rates (i.e. 1300 mol (mol Rh)-1 h-1 for 3,3-dimethyl-1-butene as T = 70°C and P = 20 bar (H2-CO)); under mild conditions the rates were only slightly affected by the alkyl substituents. The selectivity towards the linear aldehyde increases progressively with substitution, from 66% for 1-octene up to 100% for 3,3-dimethyl-1-butene, and the proportion of isomerized alkenes remained substantial (up to 17.4% for allylcyclohexane). The differences between the two systems are explained in terms of the different kinetics observed for them.

7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasopastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is 0, if Z is STR3 then Y cannot be O, and Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 --5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.